US Customs Clears OKYO Pharma’s GMP Packaged OK-101 Drug For Phase 2 Clinical Trial for Treating Dry Eye Disease
OKYO Pharma Limited ((LSE: OKYO, NASDAQ:OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this